期刊文献+

GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells 被引量:8

GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells
下载PDF
导出
摘要 AIM:To investigate the effect of GW4064 on the expression of adipokines and their receptors during differentiation of 3T3-L1 preadipocytes and in HepG2cells.METHODS:The mRNA expression of farnesoid X receptor(FXR),peroxisome proliferator-activated receptor-gamma 2(PPAR-γ2),adiponectin,leptin,resistin,adiponectin receptor 1(AdipoR1),adiponectin receptor2(AdipoR2),and the long isoform of leptin receptor(OB-Rb)and protein levels of adiponectin,leptin,andresistin were determined using fluorescent real-time PCR and enzyme linked immunosorbent assay,respectively,on days 0,2,4,6,and 8 during the differentiation of 3T3-L1 preadipocytes exposed to GW4064.Moreover,mRNA expression of AdipoR2 and OB-Rb was also examined using fluorescent real-time PCR at 0,12,24,and 48 h in HepG2 cells treated with GW4064.RESULTS:The mRNA expression of FXR,PPAR-γ2,adiponectin,leptin,resistin,AdipoR1,AdipoR2,and OB-Rb and protein levels of adiponectin,leptin,and resistin increased along with differentiation of 3T3-L1preadipocytes(P<0.05 for all).The mRNA expression of FXR,PPAR-γ2,adiponectin,leptin,and AdipoR2in 3T3-L1 preadipocytes,and AdipoR2 and OB-Rb in HepG2 cells was significantly increased after treatment with GW4064,when compared with the control group(P<0.05 for all).A similar trend was observed for protein levels of adipokines(including adiponectin,leptin and resistin).However,the expression of resistin,AdipoR1,and OB-Rb in 3T3-L1 cells did not change after treatment with GW4064.CONCLUSION:The FXR agonist through regulating,at least partially,the expression of adipokines and their receptors could offer an innovative way for counteracting the progress of metabolic diseases such as nonalcoholic fatty liver disease. AIM: To investigate the effect of GW4064 on the expression of adipokines and their receptors during differentiation of 3T3-L1 preadipocytes and in HepG2 cells.
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第42期15727-15735,共9页 世界胃肠病学杂志(英文版)
基金 Supported by Guangdong Provincial Science and Technology Projects,No.2011B050400009 Scientific Research Projects of Hubei Province Education Department,No.B2014055
关键词 Farnesoid X receptor ADIPOKINES Adipo-kine RECEPTO Farnesoid X receptor Adipokines Adipokine receptors 3T3-L1 cells HepG2 cells Nonalcoholic fatty liver disease
  • 相关文献

参考文献12

  • 1Xiao-Dong Huang,Yan Fan,Hen Zhang,Ping Wang,Jing Ping Yuan,Ming-Jie Li,Xi-Yan Zhan.Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease[J].World Journal of Gastroenterology,2008,14(18):2888-2893. 被引量:26
  • 2胡中伟,郭家伟,邓西龙.非酒精性脂肪肝与血清瘦素和胰岛素抵抗关系[J].南方医科大学学报,2006,26(6):853-855. 被引量:10
  • 3Elika Safar Zadeh,Andreea O. Lungu,Elaine K. Cochran,Rebecca J. Brown,Marc G. Ghany,Theo Heller,David E. Kleiner,Phillip Gorden.The liver diseases of lipodystrophy: The long-term effect of leptin treatment[J].Journal of Hepatology.2013(1)
  • 4Hideki Fujii,Norifumi Kawada.Inflammation and fibrogenesis in steatohepatitis[J].Journal of Gastroenterology.2012(3)
  • 5J. K.Dowman,M. J.Armstrong,J. W.Tomlinson,P. N.Newsome.Current therapeutic strategies in non‐alcoholic fatty liver disease[J].Diabetes Obesity and Metabolism.2011(8)
  • 6Christopher D. Williams,Joel Stengel,Michael I. Asike,Dawn M. Torres,Janet Shaw,Maricela Contreras,Cristy L. Landt,Stephen A. Harrison.Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study[J].Gastroenterology.2011(1)
  • 7Feng Zhang,Yin Lu,Shizhong Zheng.Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fibrogenesis[J].Cellular Signalling.2011(3)
  • 8Zhao-Xia Yang,Wei Shen,Hang Sun.Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease[J].Hepatology International.2010(4)
  • 9Leyla Nazal,Arnoldo Riquelme,Nancy Solís,Margarita Pizarro,Alex Escalona,Mauricio Burotto,Juan Ignacio Méndez,Catalina Saint-Jean,María José Concha,Stefano Giovanni,Diego Awruch,Arturo Morales,Rene Baudrand,Gonzalo Carrasco,María Angélica Domínguez,Oslando Padilla,Manuel Espinoza,Juan Francisco Miquel,Flavio Nervi,Marco Arrese.Hypoadiponectinemia and its Association with Liver Fibrosis in Morbidly Obese Patients[J].Obesity Surgery.2010(10)
  • 10Songwen Zhang,Juan Wang,Qiangyuan Liu,Douglas C. Harnish.Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis[J].Journal of Hepatology.2009(2)

二级参考文献30

  • 1[1]Stenvinkel P,Lonnqvist F,Schalling M.Molecular studies of leptin:implications for renal disease.Nephrol Dial Transplant 1999; 14:1103-1112
  • 2[2]Tartaglia LA,Dembski M,Weng X,Deng N,Culpepper J,Devos R,Richards GJ,Campfield LA,Clark FT,Deeds J,Muir C,Sanker S,Moriarty A,Moore KJ,Smutko JS,Mays GG,Wool EA,Monroe CA,Tepper RI.Identification and expression cloning of a leptin receptor,OB-R.Cell 1995; 83:1263-1271
  • 3[3]Lammert A,Kiess W,Bottner A,Glasow A,Kratzsch J.Soluble leptin receptor represents the main leptin binding activity in human blood.Biochem Biophys Res Commun 2001; 283:982-988
  • 4[4]Lahlou N,Clement K,Carel JC,Vaisse C,Lotton C,Le Bihan Y,Basdevant A,Lebouc Y,Froguel P,Roger M,Guy-Grand B.Soluble leptin receptor in serum of subjects with complete resistance to leptin:relation to fat mass.Diabetes 2000; 49:1347-1352
  • 5[5]Angulo P.Nonalcoholic fatty liver disease.N Engl J Med 2002;346:1221-1231
  • 6[6]Sheth SG,Gordon FD,Chopra S.Nonalcoholic steatohepatitis.Ann Intern Med 1997; 126:137-145
  • 7[7]Day CP,James OF.Hepatic steatosis:innocent bystander or guilty party? Hepatology 1998; 27-1463-1466
  • 8[8]Chitturi S,Farrell G,Frost L,Kriketos A,Lin R,Fung C,Liddle C,Samarasinghe D,George J.Serum leptin in NASH correlates with hepatic steatosis but not fibrosis:a manifestation of lipotoxicity? Hepatology 2002; 36:403-409
  • 9[9]Uygun A,Kadayifci A,Yesilova Z,Erdil A,Yaman H,Saka M,Deveci MS,Bagci S,Gulsen M,Karaeren N,Dagalp K.Serum leptin levels in patients with nonalcoholic steatohepatitis.Am J Gastroentero12000; 95:3584-3589
  • 10[10]Giannini E,Botta F,Cataldi A,Tenconi GL,Ceppa P,Barreca T,Testa R.Leptin levels in nonalcoholic steatohepatitis and chronic hepatitis C.Hepatogastroenterology 1999; 46:2422-2425

共引文献60

同被引文献28

引证文献8

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部